6dcg
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology== | ==Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology== | ||
- | <StructureSection load='6dcg' size='340' side='right' caption='[[6dcg]], [[Resolution|resolution]] 1.45Å' scene=''> | + | <StructureSection load='6dcg' size='340' side='right'caption='[[6dcg]], [[Resolution|resolution]] 1.45Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[6dcg]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DCG OCA]. For a <b>guided tour on the structure components</b> use [http:// | + | <table><tr><td colspan='2'>[[6dcg]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DCG OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6DCG FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=G67:(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)-N-(3-{6-[(propan-2-yl)oxy]pyridin-3-yl}-1H-indazol-5-yl)pyrrolidine-3-carboxamide'>G67</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=G67:(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)-N-(3-{6-[(propan-2-yl)oxy]pyridin-3-yl}-1H-indazol-5-yl)pyrrolidine-3-carboxamide'>G67</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase Mitogen-activated protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.24 2.7.11.24] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase Mitogen-activated protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.24 2.7.11.24] </span></td></tr> | ||
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6dcg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dcg OCA], [http://pdbe.org/6dcg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dcg RCSB], [http://www.ebi.ac.uk/pdbsum/6dcg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dcg ProSAT]</span></td></tr> |
</table> | </table> | ||
== Function == | == Function == | ||
Line 21: | Line 21: | ||
==See Also== | ==See Also== | ||
- | *[[Mitogen-activated protein kinase|Mitogen-activated protein kinase]] | + | *[[Mitogen-activated protein kinase 3D structures|Mitogen-activated protein kinase 3D structures]] |
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
+ | [[Category: Large Structures]] | ||
[[Category: Mitogen-activated protein kinase]] | [[Category: Mitogen-activated protein kinase]] | ||
[[Category: Alhassan, A B]] | [[Category: Alhassan, A B]] |
Revision as of 09:04, 11 November 2020
Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
|
Categories: Large Structures | Mitogen-activated protein kinase | Alhassan, A B | Bishop, R | Boga, S B | Buevich, A | Carr, D | Cooper, A | Cox, K | Dayananth, P | Deng, Y | Desai, J | Doll, R | Gao, X | Gudipati, S | Hesk, D | Hruza, A W | Jin, W | Kelly, J | Kirschmeier, P | Liu, G | Long, B | Mei, H | Muppalla, K | Nan, Y | Paliwal, S | Patel, M | Samatar, A A | Sherborne, B | Shih, N | Shipps, G W | Sun, R | Taylor, S A | Tsui, H | Wang, J | Wang, T | Windsor, W T | Xiao, L | Yao, X | Zhang, L | Zhu, H | Zhu, L | Kinase inhibitor | Kinase selectivity | Map kinase | Serine/ threonine-protein kinase | Transferase | Transferase-transferase inhibitor complex